{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:50:00Z","timestamp":1774896600870,"version":"3.50.1"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030970","name":"Janssen-Cilag Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030970","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,2,21]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Psoriatic arthritis (PsA) phenotypes are typically defined by their clinical components, which may not reflect patients\u2019 overlapping symptoms. This post hoc analysis aimed to identify hypothesis-free PsA phenotype clusters using machine learning to analyse data from the phase III DISCOVER-1\/DISCOVER-2 clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Pooled data from bio-na\u00efve patients with active PsA receiving guselkumab 100 mg every 8\/4 weeks were retrospectively analysed. Non-negative matrix factorisation was applied as an unsupervised machine learning technique to identify PsA phenotype clusters; baseline patient characteristics and clinical observations were input features. Minimal disease activity (MDA), disease activity index for psoriatic arthritis (DAPSA) low disease activity (LDA) and DAPSA remission at weeks 24 and 52 were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eight clusters (n=661) were identified: cluster 1 (feet dominant), cluster 2 (male, overweight, psoriasis dominant), cluster 3 (hand dominant), cluster 4 (dactylitis dominant), cluster 5 (enthesitis, large joints), cluster 6 (enthesitis, small joints), cluster 7 (axial dominant) and cluster 8 (female, obese, large joints). At week 24, MDA response was highest in cluster 2 and lowest in clusters 3, 5 and 6; at week 52, it was highest in cluster 2 and lowest in cluster 5. At weeks 24 and 52, DAPSA LDA and remission were highest in cluster 2 and lowest in clusters 4 and 6, respectively. All clusters improved with guselkumab treatment over 52 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Unsupervised machine learning identified eight PsA phenotype clusters with significant differences in demographics, clinical features and treatment responses. In the future, such data could help support individualised treatment decisions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002934","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T10:17:10Z","timestamp":1680257830000},"page":"e002934","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-na\u00efve population of patients with PsA"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct03796858","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03162796","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03158285","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04929210","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2132-4074","authenticated-orcid":false,"given":"Pascal","family":"Richette","sequence":"first","affiliation":[{"name":"Rheumatology Department, AP-HP, Lariboisi\u00e8re Hospital, INSERM U1132, Paris, France"},{"name":"Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijn","family":"Vis","sequence":"additional","affiliation":[{"name":"Rheumatology, Erasmus MC Universitair Medisch Centrum, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5943-4688","authenticated-orcid":false,"given":"Sarah","family":"Ohrndorf","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-4125","authenticated-orcid":false,"given":"William","family":"Tillett","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, UK"},{"name":"Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitari Cl\u00ednic and IDIBAPS, Universidad de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlies","family":"Neuhold","sequence":"additional","affiliation":[{"name":"EMEA Medical Affairs Immunology, Janssen-Cilag, Zug, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"van Speybroeck","sequence":"additional","affiliation":[{"name":"Janssen Pharmaceutica, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Theander","sequence":"additional","affiliation":[{"name":"EMEA Medical Affairs Immunology, Janssen-Cilag, Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Noel","sequence":"additional","affiliation":[{"name":"EMEA Medical Affairs Immunology, Janssen-Cilag BV, Breda, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6063-3000","authenticated-orcid":false,"given":"Miriam","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"EMEA Medical Affairs Immunology, Janssen-Cilag, Zug, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Shawi","sequence":"additional","affiliation":[{"name":"Medical Affairs, Janssen Global Services LLC, Horsham, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa","family":"Kollmeier","sequence":"additional","affiliation":[{"name":"Research and Development, Immunology, Janssen Research and Development LLC, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-464X","authenticated-orcid":false,"given":"Alen","family":"Zabotti","sequence":"additional","affiliation":[{"name":"Department of Medical and Biological Sciences, Rheumatology Institute, University of Udine, Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"2025090313583472000_9.1.e002934.1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"2025090313583472000_9.1.e002934.2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.41553","article-title":"Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis","volume":"73","author":"McInnes","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090313583472000_9.1.e002934.3","first-page":"19","article-title":"Epidemiology of psoriasis and psoriatic arthritis","volume":"59 Suppl 1","author":"Cimmino","year":"2007","journal-title":"Reumatismo"},{"key":"2025090313583472000_9.1.e002934.4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313583472000_9.1.e002934.5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313583472000_9.1.e002934.6","doi-asserted-by":"crossref","first-page":"108397","DOI":"10.1016\/j.clim.2020.108397","article-title":"Comorbidities associated with psoriatic arthritis: review and update","volume":"214","author":"Perez-Chada","year":"2020","journal-title":"Clin Immunol"},{"key":"2025090313583472000_9.1.e002934.7","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/1756-185X.13553","article-title":"Systematic review of depression and anxiety in psoriatic arthritis","volume":"22","author":"Kamalaraj","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2025090313583472000_9.1.e002934.8","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016400","article-title":"Obesity in psoriatic arthritis: comparative prevalence and associated factors","volume":"98","author":"Queiro","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2025090313583472000_9.1.e002934.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2025090313583472000_9.1.e002934.10","doi-asserted-by":"crossref","first-page":"105175","DOI":"10.1016\/j.jbspin.2021.105175","article-title":"A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: a call to action","volume":"88","author":"Gratac\u00f3s","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2025090313583472000_9.1.e002934.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220991"},{"key":"2025090313583472000_9.1.e002934.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8"},{"key":"2025090313583472000_9.1.e002934.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4"},{"key":"2025090313583472000_9.1.e002934.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220454"},{"key":"2025090313583472000_9.1.e002934.15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002750","article-title":"Patterns of joint involvement in juvenile idiopathic arthritis and prediction of disease course: a prospective study with multilayer non-negative matrix factorization","volume":"16","author":"Eng","year":"2019","journal-title":"PLoS Med"},{"key":"2025090313583472000_9.1.e002934.16","doi-asserted-by":"publisher","DOI":"10.1038\/44565"},{"key":"2025090313583472000_9.1.e002934.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2025090313583472000_9.1.e002934.18","first-page":"S64","article-title":"Measures of psoriatic arthritis: tender and swollen joint assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI)","volume":"63 Suppl 11","author":"Mease","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313583472000_9.1.e002934.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209511"},{"key":"2025090313583472000_9.1.e002934.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214140"},{"key":"2025090313583472000_9.1.e002934.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.514"},{"key":"2025090313583472000_9.1.e002934.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0147-9"},{"key":"2025090313583472000_9.1.e002934.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210724"},{"key":"2025090313583472000_9.1.e002934.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"2025090313583472000_9.1.e002934.25","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313583472000_9.1.e002934.26","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025090313583472000_9.1.e002934.27","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"Lancet Rheumatology"},{"key":"2025090313583472000_9.1.e002934.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218808"},{"key":"2025090313583472000_9.1.e002934.29","unstructured":"ClinicalTrials.gov . A study of guselkumab administered subcutaneously in bio-naive participants with active psoriatic arthritis axial disease (STAR). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04929210 [Accessed Dec 2022]."},{"key":"2025090313583472000_9.1.e002934.30","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150114"},{"key":"2025090313583472000_9.1.e002934.31","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200004)43:4<865::AID-ANR18>3.0.CO;2-W"},{"key":"2025090313583472000_9.1.e002934.32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-3083.2009.03363.x","article-title":"Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease","volume":"23 Suppl 1","author":"McGonagle","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090313583472000_9.1.e002934.33","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l886","article-title":"Clinical applications of machine learning algorithms: beyond the black box","volume":"364","author":"Watson","year":"2019","journal-title":"BMJ"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:58:46Z","timestamp":1756933126000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,31]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/rmdopen-2022-002934"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002934","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}